180 related articles for article (PubMed ID: 38713229)
1. Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer.
Liu Y; Li M; Fang Z; Gao S; Cheng W; Duan Y; Wang X; Feng J; Yu T; Zhang J; Wang T; Hu A; Zhang H; Rong Z; Shakila SS; Shang Y; Kong F; Liu J; Li Y; Ma F
Cancer Immunol Immunother; 2024 May; 73(7):117. PubMed ID: 38713229
[TBL] [Abstract][Full Text] [Related]
2. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer.
Ding S; Qiao N; Zhu Q; Tong Y; Wang S; Chen X; Tian Q; Xiao Y; Shen K
Cancer Commun (Lond); 2023 Jun; 43(6):661-684. PubMed ID: 37158690
[TBL] [Abstract][Full Text] [Related]
3. Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.
Johnson J; Rychahou P; Sviripa VM; Weiss HL; Liu C; Watt DS; Evers BM
PLoS One; 2019; 14(3):e0209392. PubMed ID: 30875375
[TBL] [Abstract][Full Text] [Related]
4. S100A9 expressed in ER(-)PgR(-) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival.
Bergenfelz C; Gaber A; Allaoui R; Mehmeti M; Jirström K; Leanderson T; Leandersson K
Br J Cancer; 2015 Oct; 113(8):1234-43. PubMed ID: 26448179
[TBL] [Abstract][Full Text] [Related]
5. Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers.
Yi J; Ren L; Li D; Wu J; Li W; Du G; Wang J
Biomed Pharmacother; 2020 Apr; 124():109827. PubMed ID: 31986408
[TBL] [Abstract][Full Text] [Related]
6. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
7. Crumbs protein homolog 3 (CRB3) expression is associated with oestrogen and progesterone receptor positivity in breast cancer.
Li P; Zhou C; Yan Y; Li J; Liu J; Zhang Y; Liu P
Clin Exp Pharmacol Physiol; 2019 Sep; 46(9):837-844. PubMed ID: 31087799
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
Wu JR; Zhao Y; Zhou XP; Qin X
Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
[TBL] [Abstract][Full Text] [Related]
9. Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer.
Park IH; Yang HN; Lee KJ; Kim TS; Lee ES; Jung SY; Kwon Y; Kong SY
Oncotarget; 2017 May; 8(20):32722-32730. PubMed ID: 28415798
[TBL] [Abstract][Full Text] [Related]
10. Analysis of differentially expressed proteins between HER2 positive and triple negative breast cancer and their prognostic significance.
Wei Z; Sijia F; Rui T; Yang L; Jianjun H; Bin W; Jing X
Ann Diagn Pathol; 2021 Dec; 55():151834. PubMed ID: 34610510
[TBL] [Abstract][Full Text] [Related]
11. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
12. The estrogen/miR-338-3p/ADAM17 axis enhances the viability of breast cancer cells via suppressing NK cell's function.
Shi Y; Pan J; Hang C; Tan L; Hu L; Yan Z; Zhu J
Environ Toxicol; 2023 Jul; 38(7):1618-1627. PubMed ID: 37052432
[TBL] [Abstract][Full Text] [Related]
13. Genomic insights into triple-negative and HER2-positive breast cancers using isogenic model systems.
Mudvari P; Ohshiro K; Nair V; Horvath A; Kumar R
PLoS One; 2013; 8(9):e74993. PubMed ID: 24086418
[TBL] [Abstract][Full Text] [Related]
14. Characterization of macrophage--cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer.
Hollmén M; Roudnicky F; Karaman S; Detmar M
Sci Rep; 2015 Mar; 5():9188. PubMed ID: 25776849
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.
Engel JB; Honig A; Kapp M; Hahne JC; Meyer SR; Dietl J; Segerer SE
Arch Gynecol Obstet; 2014 Jan; 289(1):141-7. PubMed ID: 23828443
[TBL] [Abstract][Full Text] [Related]
16. All-trans-retinoic acid modulates glycolysis via H19 and telomerase: the role of mir-let-7a in estrogen receptor-positive breast cancer cells.
El Habre R; Aoun R; Tahtouh R; Hilal G
BMC Cancer; 2024 May; 24(1):615. PubMed ID: 38773429
[TBL] [Abstract][Full Text] [Related]
17. Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.
O'Meara T; Safonov A; Casadevall D; Qing T; Silber A; Killelea B; Hatzis C; Pusztai L
Breast Cancer Res Treat; 2019 May; 175(1):247-259. PubMed ID: 30725384
[TBL] [Abstract][Full Text] [Related]
18. Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer Subtypes.
Vishnubalaji R; Alajez NM
Cells; 2023 Apr; 12(8):. PubMed ID: 37190091
[TBL] [Abstract][Full Text] [Related]
19. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
[TBL] [Abstract][Full Text] [Related]
20. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
